Skip to content
drillr.ai
Sign up

TEM

Tempus AI, Inc.

NASDAQ · Healthcare · Medical - Healthcare Information Services · US

$64.70
+0.06%
Ask drillr

  • Aug 24, 2026, 12:30 UTC

    Tempus AI, Inc. received FDA 510(k) clearance for its AI-enabled software device Tempus ECG-PH, which analyzes standard 12-lead ECGs to detect signs of pulmonary hypertension.

    Source:

  • Aug 22, 2026, 07:03 UTC

    Tempus AI shares rose 8.3% in mid-day trading on Friday after BTIG Research raised its price target from $70.00 to $80.00.

    Source:

  • Aug 20, 2026, 07:24 UTC

    Bank of America Corp DE reduced its stake in Tempus AI, Inc. by 63.6% during the quarter, selling 725,709 shares and retaining 414,780 shares, as disclosed in its 13F filing with the SEC.

    Source:

  • Aug 13, 2026, 14:11 UTC

    Tempus AI received FDA approval for its xT product, potentially enabling higher pricing and reimbursement.

    Source:

  • Aug 11, 2026, 07:00 UTC

    Bios Life announced a multi-year partnership with Tempus, including commercial rights to BioNTech-InstaDeep's genomics AI.

    Source:

  • Aug 6, 2026, 13:15 UTC

    CellCarta announced a strategic collaboration with Tempus AI to add Tempus as a second commercial laboratory partner in its CDx commercialization lab network, supporting oncology-focused access within CellCarta's CDx Accelerator Model.

    Source:

  • Aug 4, 2026, 18:04 UTC

    Wohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.

    Source:

  • Jul 30, 2026, 20:01 UTC

    Tempus AI, Inc. reported financial results for the second quarter of 2026.

    Source:

  • Jul 22, 2026, 12:30 UTC

    Tempus AI launched its OneOme pharmacogenomics testing solution nationally in the United States.

    Source:

  • Jul 20, 2026, 12:31 UTC

    TEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.

    Source:

  • Jun 25, 2026, 12:30 UTC

    Tempus AI, Inc. announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma.

    Source:

  • Jun 9, 2026, 10:00 UTC

    Ambry Genetics announced peer-reviewed research demonstrating the potential of its ExomeReveal RNA testing to improve diagnostic clarity in exome testing.

    Source:

  • Jun 3, 2026, 12:30 UTC

    Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center launched a digital pathology open-source consortium.

    Source:

  • May 31, 2026, 12:30 UTC

    Tempus AI, Inc. launched the next-generation of its Lens agentic AI platform for oncology drug development.

    Source:

  • May 30, 2026, 12:30 UTC

    Tempus AI launched the PRECISION Challenge, a national program providing access to its foundation model, data, and funding to accelerate oncology research.

  • May 30, 2026, 12:00 UTC

    Tempus AI, Inc. launched Tempus Preview, an application that provides rapid preliminary genomic insights within 24 hours of tissue receipt for precision oncology workflows.

    Source: